RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue15193471
Cost of Revenue5,3705,4156,9255,680
Gross Profit-5,355-5,396-6,891-5,609
Operating Expenses
Research Development----
Selling General and Administrative4,0113,6193,3463,217
Non Recurring----
Total Operating Expenses9,3819,03410,2718,897
Operating Income or Loss-9,366-9,015-10,237-8,826
Income from Continuing Operations
Total Other Income/Expenses Net-4,707211426
Earnings Before Interest and Taxes-9,366-9,015-10,237-8,826
Interest Expense-1-1-1-1
Income Before Tax-14,073-8,994-10,223-8,800
Income Tax Expense-1,621---
Minority Interest----
Net Income From Continuing Ops-12,452-8,994-10,223-8,800
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-12,452-8,994-10,223-8,800
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-12,452-11,069-10,432-12,930